Back to Oncology
Oncologyv2018Evidence-Based

PROMISE Score for Malignant Pleural Effusion

Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.

Clinical Input Parameters

g/dL
×10⁹ cells/L
mg/L
Clinical Assessment
Awaiting Parameters
promise score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The PROMISE Score for Malignant Pleural Effusion is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Sum of weighted points from: Previous chemotherapy (0-4), Previous radiotherapy (0-2), Hemoglobin level (0-4), WBC count (0-9), CRP level (0-11), ECOG status (0-7), Cancer type (0-6)

Clinical Pearls & Practice Notes

  • First prospectively validated prognostic model for malignant pleural effusion
  • Combines clinical and biological parameters for accurate 3-month mortality prediction
  • Superior to LENT score and ECOG Performance Status alone in predicting survival
  • Helps guide treatment decisions including pleurodesis, drainage procedures, and palliative care
  • Validated across multiple cancer types including lung cancer, breast cancer, and mesothelioma
  • Can be used to stratify patients in clinical trials and research studies
  • Assists in prognostic discussions with patients and families
  • Lower scores indicate candidates for aggressive interventions including pleurodesis
  • Higher scores suggest focus on symptom palliation and comfort care
  • Regular reassessment may be needed as clinical status changes
  • Should be interpreted within the context of overall clinical picture
  • Useful for healthcare resource planning and quality improvement initiatives

Evidence & Literature Citations

  1. Psallidas I, Kanellakis NI, Gerry S, Thakur N, Bamber J, Dipper A, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8.
  2. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098-104. doi: 10.1136/thoraxjnl-2014-205285.
  3. Yap E, Anderson B, Nair A, Vaska K, Ferland L, Penney B, et al. The role of LENT and PROMISE scores in predicting survival in malignant pleural effusion. Lung. 2022;200(4):459-465. doi: 10.1007/s00408-022-00547-5.

Score Interpretation Ranges

Low Risk0 – 20 pts

3-month mortality <25%

Intermediate-Low Risk21 – 30 pts

3-month mortality 25-50%

Intermediate-High Risk31 – 40 pts

3-month mortality 50-75%

High Risk41 – 80 pts

3-month mortality >75%

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.